newsfilter
← Latest News
PR Newswire·

Oramed Letter to Shareholders

Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023Phase 2 NASH Trial Achieved Primary and Secondary EndpointsDefinitive Deal Signed to Commercialize Oral Insulin in South Korea $160 Million in Cash and